EQ Projected Dividend Yield
Equillium Inc ( NASDAQ : EQ )Equillium, Inc. is a clinical-stage biotechnology company. It is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. Co.'s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. Co.'s EQ101 is a selective tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15. The EQ302 is an orally delivered, selective bi-specific cytokine inhibitor targeting IL-15 and IL-21. It is in pre-clinical development. 20 YEAR PERFORMANCE RESULTS |
EQ Dividend History Detail EQ Dividend News EQ Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |